ABL Bio Inc
KOSDAQ:298380
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ABL Bio Inc
Gain/Loss on Disposition of Assets
ABL Bio Inc
Gain/Loss on Disposition of Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gain/Loss on Disposition of Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Gain/Loss on Disposition of Assets
-₩8.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Gain/Loss on Disposition of Assets
₩90.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Gain/Loss on Disposition of Assets
₩31B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
165%
|
CAGR 10-Years
N/A
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Gain/Loss on Disposition of Assets
₩256.3m
|
CAGR 3-Years
133%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Gain/Loss on Disposition of Assets
₩13.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Gain/Loss on Disposition of Assets
-₩10.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
ABL Bio Inc
Glance View
ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.
See Also
What is ABL Bio Inc's Gain/Loss on Disposition of Assets?
Gain/Loss on Disposition of Assets
-8.5m
KRW
Based on the financial report for Dec 31, 2025, ABL Bio Inc's Gain/Loss on Disposition of Assets amounts to -8.5m KRW.
What is ABL Bio Inc's Gain/Loss on Disposition of Assets growth rate?
Gain/Loss on Disposition of Assets CAGR 5Y
-32%
Over the last year, the Gain/Loss on Disposition of Assets growth was -21%.
